GSK’s Zejula meets primary endpoint in Phase 3 trial of patients with ovarian cancer

pharmafile | July 15, 2019 | News story | Sales and Marketing  

British multinational GlaxoSmithKline has said ovarian cancer drug Zejula (niraparib) met its primary endpoint in a Phase 3 trial.

Zejula showed a statistically significant improvement in progression free survival in women with first-line ovarian cancer who had undergone platinum-based chemotherapy regardless of their biomarker status. The safety and tolerability of the drug was consistent with previous clinical trials.

GSK gained the rights to Zejula, an orally active small molecule PARP inhibitor, after acquiring the Massachusetts-based firm Tesaro for $5.1 billion in 2018. PARP inhibitors work by blocking enzymes involved in repairing damaged DNA.

Dr Hal Barron, Chief Scientific Officer and President, R&D, GSK, commented: “Almost 300,000 women around the world are diagnosed with ovarian cancer every year, yet only about 15% of patients are currently eligible to receive PARP inhibitors as their initial therapy. These exciting data demonstrate that ZEJULA has the potential to significantly benefit even more women with this devastating cancer.”

Louis Goss

Related Content

No items found

Latest content